{"gene":"GSDMD","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2015,"finding":"Inflammatory caspases (caspase-1, -4, -5, and -11) cleave GSDMD at the linker between the N-terminal gasdermin-N domain and C-terminal gasdermin-C domain. Cleavage releases the intramolecular autoinhibition imposed by the C-terminal domain on the N-terminal domain, and the freed N-terminal domain is necessary and sufficient to induce pyroptotic cell death. GSDMD-deficient cells resist pyroptosis induced by cytosolic LPS and canonical inflammasome ligands, and IL-1β release is diminished despite intact caspase-1 processing.","method":"CRISPR-Cas9 genome-wide screen in mouse bone marrow macrophages; GSDMD knockout cells; domain-mapping experiments with cleavage-resistant and N-terminal-only constructs","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — genome-wide genetic screen with rigorous functional follow-up, domain mapping, and loss-of-function confirmed by multiple orthogonal methods; widely replicated","pmids":["26375003"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of the human GSDMD C-terminal domain (2.64 Å) reveals that the first loop of GSDMD-C inserts into GSDMD-N to stabilize autoinhibited conformation. The positive-potential surface of GSDMD-N (covered by GSDMD-C in the intact protein) is exposed after caspase cleavage and drives high-order oligomerization via charge-charge interactions. A short segment of GSDMD-N is sufficient to kill bacteria in vitro. SAXS envelope of human GSDMD is consistent with an autoinhibited conformation in solution.","method":"X-ray crystallography (GSDMD-C, 2.64 Å); small-angle X-ray scattering (SAXS); site-directed mutagenesis (F283A/F283R); cell-death assays in 293T cells; in vitro bactericidal assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with SAXS and mutagenesis with functional validation in cells and in vitro","pmids":["28928145"],"is_preprint":false},{"year":2020,"finding":"Autoprocessing of caspase-4/11 generates a p10 fragment that binds the GSDMD C-terminal domain with high affinity via a hydrophobic interface induced by the autoprocessing-generated β-sheet. Crystal structures of autoprocessed caspase-4/11–GSDMD-C and caspase-1–GSDMD-C complexes reveal a conserved C-domain recognition mode. This C-domain binding promotes dimerization-mediated caspase activation and allows cleavage of GSDMD independently of the canonical cleavage-site tetrapeptide sequence.","method":"Crystal structures of caspase-4/11-GSDMD-C and caspase-1-GSDMD-C complexes; biochemical binding assays; autoprocessing mutants; pyroptosis cell assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple crystal structures with mutagenesis and biochemical validation in a single rigorous study","pmids":["32109412"],"is_preprint":false},{"year":2018,"finding":"Calcium influx through GSDMD pores in the plasma membrane serves as a signal for cells to recruit the ESCRT-III membrane-repair machinery to damaged membrane areas. Inhibition of ESCRT-III strongly enhances pyroptosis and IL-1β release after canonical or noncanonical inflammasome activation, demonstrating that ESCRT-mediated membrane repair acts downstream of GSDMD pore formation to counteract pyroptotic cell death.","method":"Live-cell calcium imaging; pharmacological and genetic inhibition of ESCRT-III; LDH/IL-1β release assays in human and murine macrophages","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (imaging, genetic KD, pharmacological inhibition) replicated in human and murine cells","pmids":["30467171"],"is_preprint":false},{"year":2019,"finding":"IRF2, an interferon regulatory factor family transcription factor, binds a unique site in the GSDMD promoter and is required for GSDMD transcription. IRF2-deficient macrophages, endothelial cells, and multiple tissues show substantially reduced GSDMD expression, with corresponding reductions in IL-1β secretion and pyroptosis. Disruption of the single IRF2-binding site abolishes both canonical and noncanonical inflammasome signaling.","method":"Forward genetic ENU mutagenesis screen in mice; IRF2 knockout macrophages and tissues; promoter binding assays; IL-1β secretion and pyroptosis assays","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo ENU screen plus mechanistic promoter binding and loss-of-function in multiple cell types","pmids":["31113851"],"is_preprint":false},{"year":2024,"finding":"GSDMD undergoes reversible S-palmitoylation at C192 during pyroptosis. The palmitoyl acyltransferase DHHC7 palmitoylates full-length GSDMD to direct its cleavage by caspases. Palmitoylation of the released GSDMD N-terminal fragment (GSDMD-NT) promotes its translocation to the plasma membrane, where the depalmitoylase APT2 then removes the palmitoyl group to unmask C192 and promote GSDMD-NT oligomerization and pore formation. Perturbation of either palmitoylation or depalmitoylation suppresses pyroptosis and increases survival in LPS-induced septic shock.","method":"Acyl-RAC palmitoylation assays; site-directed mutagenesis of C192; DHHC7 and APT2 knockout/knockdown; subcellular fractionation; in vivo LPS sepsis model with GSDMD-KO and enzyme-KO mice","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical reconstitution of palmitoylation cycle, mutagenesis, enzyme identification, and in vivo validation with multiple orthogonal methods","pmids":["38538834"],"is_preprint":false},{"year":2024,"finding":"In brain endothelial cells (bECs), LPS is internalized via the LBP-CD14 pathway and activates caspase-11 (CASP11), which cleaves GSDMD to cause plasma membrane permeabilization and pyroptosis, leading to BBB disruption. Mice deficient in LBP-CD14 or GSDMD resist LPS-induced BBB breakdown. bEC-targeted delivery of active GSDMD-N opens the BBB independently of LPS. A GSDMD-neutralizing nanobody expressed in bECs prevents K. pneumoniae infection-induced BBB disruption in CASP4-humanized mice.","method":"Mouse genetics (GSDMD-KO, LBP/CD14-KO, CASP4-humanized mice); bEC-targeting AAV nanobody delivery; electron microscopy of disrupted BBB; in vitro pyroptosis assays; single-cell RNA-seq","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — comprehensive mouse genetic analyses with multiple KO strains, viral delivery, nanobody rescue, and EM structural validation","pmids":["38632402"],"is_preprint":false},{"year":2024,"finding":"Nanobodies (VHHs) raised against human GSDMD that are expressed cytosolically prevent GSDMD-NT oligomerization but not membrane insertion, showing that membrane insertion of GSDMD-NT monomers precedes oligomerization during pore formation. Inhibition of GSDMD pore formation by nanobodies switches cell death from pyroptosis to apoptosis, driven by enhanced caspase-1 activity activating caspase-3. Recombinant antagonistic nanobodies added extracellularly also prevent pyroptosis.","method":"Intracellular nanobody expression; extracellular nanobody addition; GSDMD-NT membrane partitioning assays; caspase activity assays; live-cell death readouts","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct mechanistic dissection of oligomerization vs. membrane insertion order using nanobody tools with multiple orthogonal readouts in a single rigorous study","pmids":["39327452"],"is_preprint":false},{"year":2020,"finding":"GSDMD-mediated pore formation in endothelial cells in response to cytosolic LPS does not cause cell death but instead restrains endothelial cell proliferation (mitochondrial GSDMD pores DAMPen pyroptosis context discussed in this commentary describing the Huang et al. finding).","method":"Commentary/perspective summarizing primary experimental findings from Huang et al. regarding endothelial GSDMD pores and cell proliferation","journal":"Immunity","confidence":"Low","confidence_rationale":"Tier 4 / Weak — this is a commentary, not a primary experimental paper; the underlying experimental data are not directly reported here","pmids":["32187511"],"is_preprint":false},{"year":2023,"finding":"GI-Y1, identified by structure-based virtual screening, binds GSDMD and inhibits its lipid-binding and pore formation by targeting the Arg7 residue of GSDMD-N. GI-Y1 also inhibits mitochondrial binding of GSDMD-N and associated mitochondrial dysfunction, and protects against myocardial I/R injury in vivo.","method":"Structure-based virtual screening; direct binding assays; site-directed mutagenesis of Arg7; liposome binding assay; in vivo myocardial I/R mouse model","journal":"Basic research in cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding and mutagenesis evidence for Arg7 as functional residue, single lab with in vivo validation","pmids":["37782407"],"is_preprint":false},{"year":2024,"finding":"GSDMD is acetylated at Lysine 248, and this acetylation enhances pyroptosis. HDAC4 acts as the specific deacetylase that deacetylates GSDMD at K248, suppressing pyroptosis. Deacetylation of GSDMD impairs its ubiquitination. Phosphorylation of HDAC4 promotes its deacetylase activity toward GSDMD. Protein phosphatase 1 (PP1α and PP1γ) dephosphorylates HDAC4 to inhibit its deacetylase activity on GSDMD, thereby enabling acetylation and pyroptosis.","method":"Mass spectrometry identification of acetylation site; site-directed mutagenesis of K248; HDAC4 knockdown/overexpression; PP1 knockdown; ubiquitination assays; in vitro and in vivo pyroptosis assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — PTM site identified and functionally validated with mutagenesis; writer/eraser identified; single lab with multiple orthogonal methods","pmids":["38326336"],"is_preprint":false},{"year":2023,"finding":"O-GlcNAcylation of GSDMD at Serine 338 (S338) prevents its interaction with caspase-11 (caspase-4 homolog) and thereby inhibits LPS-induced pyroptosis in endothelial cells. Increased O-GlcNAc stimulation in septic mice reduces endothelial injury and GSDMD cleavage.","method":"O-GlcNAcylation site prediction and gene mutation (S338A); Co-IP to assess caspase-4/GSDMD interaction; OGA inhibitor thiamet-G treatment in HUVECs and septic mice; western blot for GSDMD cleavage","journal":"Inflammation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — PTM site identified by mutagenesis and interaction assay; single lab with in vitro and in vivo evidence","pmids":["37962578"],"is_preprint":false},{"year":2025,"finding":"The E3 ligase TRIM21 catalyzes K33-linked polyubiquitination of GSDMD-NT at Lys51, enabling recognition by the cargo receptor SQSTM1/p62 and subsequent selective autophagy-mediated degradation of p30/GSDMD-NT. Scutellarin exploits this pathway to inhibit pyroptosis by degrading p30/GSDMD-NT and by blocking ASC oligomerization.","method":"Ubiquitination assays with linkage-specific antibodies; K51R mutagenesis; TRIM21 and p62 knockdown; autophagy flux assays; multiple inflammasome activation models","journal":"Pharmacological research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — PTM (K33-ubiquitin at K51) identified with mutagenesis and E3 ligase identified; single lab with multiple orthogonal methods","pmids":["39824372"],"is_preprint":false},{"year":2024,"finding":"METTL3-mediated m6A modification of GSDMD mRNA is recognized by the m6A reader YTHDF2, which decreases GSDMD mRNA stability and suppresses GSDMD-mediated pyroptosis in breast cancer cells. METTL3 inhibition restores GSDMD expression and enhances pyroptosis.","method":"m6A-seq/MeRIP; YTHDF2 RIP assay; mRNA stability assays; METTL3 and YTHDF2 knockdown/overexpression; pyroptosis readouts; in vivo tumor model with METTL3 inhibitor","journal":"Apoptosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — m6A writer and reader identified with RNA immunoprecipitation and functional rescue; single lab","pmids":["39627574"],"is_preprint":false},{"year":2024,"finding":"SNORD99 promotes 2'-O-methylation of GSDMD mRNA, forming a SNORD99-FBL RNP complex. This modification reduces GSDMD protein levels, thereby suppressing caspase-1/NLRP3-dependent pyroptosis and promoting endometrial cancer progression.","method":"RTL-P assay for 2'-O-methylation; RNA-seq after SNORD99 overexpression; co-immunoprecipitation of SNORD99-FBL RNP; ASO-mediated SNORD99 suppression; western blot for GSDMD/caspase-1/NLRP3; electron/optical microscopy of pyroptosis","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — novel RNA modification of GSDMD identified with RTL-P and RNP pulldown; single lab with multiple methods","pmids":["39450788"],"is_preprint":false},{"year":2024,"finding":"GSDMD contributes to mitochondrial dysfunction during pyroptosis: the pore-forming N-terminal of GSDMD localizes to mitochondria (in addition to the plasma membrane) following caspase-dependent cleavage, causing abnormal mitochondrial aggregation and oxidative stress in cochlear marginal cells, which drives inflammation, stria vascularis damage, and cisplatin-induced hearing loss.","method":"Gsdmd-KO mice; pharmacological GSDMD inhibition (necrosulfonamide, disulfiram); confocal and electron microscopy for GSDMD-N mitochondrial localization; ROS/membrane potential assays; RNA-seq; cochlear histology","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization of GSDMD-N to mitochondria functionally linked to mitochondrial dysfunction; validated with KO mice and pharmacological inhibition using multiple readouts","pmids":["40067887"],"is_preprint":false},{"year":2024,"finding":"A small molecule DMB (6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline) directly activates GSDMD pore formation and pyroptosis without requiring caspase-mediated cleavage of GSDMD, demonstrating that GSDMD can be activated independently of proteolytic processing. Low-level DMB-induced pyroptosis in tumor cells stimulates immune-mediated antitumor responses.","method":"High-throughput chemical screen; direct GSDMD pore-formation assays; liposome leakage; tumor models in lymphocyte-deficient mice; cytokine measurements; anti-PD-1 combination studies","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of GSDMD pore formation by small molecule; mechanistic selectivity confirmed; multiple in vivo models","pmids":["39243763"],"is_preprint":false},{"year":2022,"finding":"Canonical inflammasomes (NLRP3, NLRC4, NLRP1b, Pyrin, AIM2) all promote GSDMD cleavage in neutrophils, and canonical inflammasome-induced pyroptosis and IL-1β secretion are blunted in GSDMD-knockout neutrophils. In contrast, GSDMD is dispensable for PMA-induced NETosis in neutrophils.","method":"GSDMD-KO bone marrow neutrophils; multiple canonical inflammasome activators; NLRP3 gain-of-function (Nlrp3-A350V) transgenic mice; LDH/IL-1β/pyroptosis readouts; PMA-NETosis assay","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — comprehensive genetic loss-of-function across multiple inflammasome platforms; clear positive and negative results for GSDMD role in pyroptosis vs. NETosis","pmids":["35899491"],"is_preprint":false},{"year":2025,"finding":"In an experimental sepsis model, NET formation was independent of GSDMD (and PAD4) but required MYD88, indicating that GSDMD is not required for sepsis-induced intravascular NET formation in vivo. Pharmacological GSDMD inhibitors did not reduce PMA-stimulated NET formation ex vivo.","method":"Gsdmd/D1/D1l3-/- triple knockout mice; LPS/E. coli sepsis model; pharmacological GSDMD inhibitors; ex vivo PMA-NET assay","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — negative result (GSDMD dispensable for in vivo NETs in sepsis) established with genetic KO and pharmacological inhibition; single lab","pmids":["39777764"],"is_preprint":false},{"year":2020,"finding":"Caspase-8 and GSDMD are both required for the development of MLKL-independent ileitis in mice with epithelial FADD deficiency, placing GSDMD downstream of caspase-8 in a pyroptosis-like death pathway in intestinal epithelial cells that is distinct from necroptosis.","method":"Genetic epistasis: IEC-specific FADD-KO, caspase-8-KO, MLKL-KO, GSDMD-KO mice and combinations; histological assessment of colitis/ileitis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean epistasis with multiple double and triple KO combinations defining pathway position in vivo","pmids":["32362323"],"is_preprint":false},{"year":2022,"finding":"GSDMD deficiency in cardiomyocytes (cardiomyocyte-specific CKO) reduces TAC-induced pyroptosis, myocardial hypertrophy, and fibrosis. GSDMD-mediated pyroptosis in this context activates JNK and p38 signaling pathways (but not ERK or Akt), linking GSDMD-driven pyroptosis to downstream kinase-mediated cardiac remodeling.","method":"Cardiomyocyte-specific GSDMD-CKO mice; TAC-induced pressure overload; echocardiography; western blot for JNK/p38/ERK/Akt phosphorylation; histology","journal":"Clinical and experimental hypertension","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO with pathway analysis; single lab","pmids":["36906959"],"is_preprint":false},{"year":2024,"finding":"GSDMD in macrophages contributes to mitochondrial perforation and mitochondrial DNA leakage, subsequently activating the STING-IRF3/NF-κB axis. GSDMD also regulates macrophage migration via cytokine secretion in the context of atherosclerosis.","method":"Gsdmd-/-ApoE-/- mice; bone marrow transplantation; AAV-F4/80-shGSDMD macrophage-specific knockdown; single-cell RNA-seq; STING pathway analysis; mtDNA leakage assays","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — macrophage-specific KD combined with mtDNA/STING pathway mechanistic analysis; single lab","pmids":["38695170"],"is_preprint":false},{"year":2023,"finding":"GSDMD-NT from pyroptotic macrophage-derived microvesicles (containing GSDMD-N-expressing mitochondria) is transferred to neutrophils via microvesicles, inducing mitochondrial dysfunction and triggering NETs formation through the mitochondrial ROS/GSDMD axis in the context of sepsis.","method":"Macrophage-neutrophil co-culture with microvesicles; flow cytometry; confocal microscopy for mitochondrial transfer; mtROS measurement; disulfiram (GSDMD inhibitor) in vivo sepsis model","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic intercellular transfer established with imaging and functional assays; single lab","pmids":["38169726"],"is_preprint":false},{"year":2022,"finding":"GSDMD knockout in GSDMD-/- mice or GSDMD knockdown (dimethyl fumarate) inhibits GSDMD activation and reduces NETs formation and mitochondrial DNA leakage into the neutrophil cytosol. GSDMD causes mtDNA to leak into the cytosol during lung ischemia/reperfusion, activating the cGAS-STING pathway and stimulating NETs formation.","method":"GSDMD-KO mice; disulfiram pharmacological inhibition; mtDNA cytoplasmic fractionation; cGAS-STING pathway inhibition; in vivo lung I/R model","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological GSDMD inhibition with mechanistic pathway (mtDNA-cGAS-STING) in vivo; single lab","pmids":["37794018"],"is_preprint":false},{"year":2023,"finding":"CHMP4B and VPS4A (ESCRT-III components) interact with GSDMD (confirmed by Co-IP) and localize as puncta at injured plasma membranes containing GSDMD-NT. Depletion of CHMP4B or VPS4A enhances GSDMD-mediated pore formation and pyroptotic indicators, while overexpression reduces them, demonstrating that the ESCRT machinery directly counteracts GSDMD pores through membrane remodeling in endometrial carcinoma cells.","method":"Co-immunoprecipitation of GSDMD with CHMP4B and VPS4A; siRNA knockdown and overexpression; electron microscopy of membrane perforations; fluorescence confocal microscopy of CHMP4B/VPS4A puncta at GSDMD-NT membrane sites; PI/LDH/IL-1β/Ca2+ assays","journal":"Biochimica et biophysica acta. General subjects","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct interaction confirmed by Co-IP with functional membrane repair readouts; single lab with multiple orthogonal methods","pmids":["37931722"],"is_preprint":false},{"year":2022,"finding":"GSDMD deficiency in the acute phase of myocardial I/R protects the heart, but in the chronic phase GSDMD deficiency aggravates injury. Mechanistically, GSDMD deficiency induces activation of poly(ADP-ribosyl)ation (PARylation) and consumption of NAD+ and ATP, leading to cardiomyocyte apoptosis. PARP-1 inhibitor PJ34 reduces injury caused by GSDMD deficiency.","method":"GSDMD-KO mice; acute and chronic I/R timepoints; PARylation assays; NAD+/ATP measurements; PJ34 pharmacological rescue; western blot and histology","journal":"Oxidative medicine and cellular longevity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with biochemical mechanism (PARylation/NAD+) and pharmacological rescue; single lab","pmids":["35783187"],"is_preprint":false},{"year":2024,"finding":"JX06 covalently modifies Cys39/Cys192 residues of GSDMD, inhibiting accumulation of GSDMD-NT and pore formation in the plasma membrane, thereby suppressing PANoptosis and multiple organ injury in heat stress and sepsis models.","method":"Covalent modification mass spectrometry; GSDMD-KO rescue experiments; in vitro pore-formation assays; in vivo heat stress and sepsis MODS models; cell death assays","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — covalent binding to specific cysteines identified by MS with in vitro pore-formation and in vivo validation; single lab","pmids":["39848475"],"is_preprint":false},{"year":2024,"finding":"GSDMD knockout reduces skeletal muscle atrophy in septic mice by blocking the IL-18/AMPK signaling pathway, and specifically reduces markers of the ubiquitin-proteasome system and autophagy pathways. GSDMD-NT levels are elevated in skeletal muscle of septic mice, linking pyroptosis execution by GSDMD to downstream IL-18 secretion that drives muscle wasting via AMPK.","method":"Gsdmd-KO mice; CLP sepsis model; siRNA knockdown in C2C12 cells; AMPK phosphorylation assays; muscle atrophy marker expression (Atrogin-1, MuRF1); IL-18 measurements","journal":"Shock","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO with defined signaling pathway (IL-18/AMPK) in vivo and in vitro; single lab","pmids":["39227368"],"is_preprint":false}],"current_model":"GSDMD is a cytosolic executioner protein that is maintained in an autoinhibited conformation by intramolecular interactions between its C-terminal (gasdermin-C) and N-terminal (gasdermin-N) domains; inflammatory caspases (caspase-1, -4, -5, -11) recognize and cleave the interdomain linker—with autoprocessed caspase-4/11 p10 engaging a hydrophobic interface on the GSDMD-C domain to drive cleavage independently of tetrapeptide sequence—releasing GSDMD-NT, which undergoes DHHC7-mediated palmitoylation at C192 to traffic to the plasma membrane, where APT2-mediated depalmitoylation unmasks C192 and enables oligomerization into large membrane pores that drive pyroptotic cell death, IL-1β/IL-18 release, and calcium influx; the ESCRT-III membrane-repair machinery is recruited downstream of calcium influx to reseal pores and antagonize pyroptosis; GSDMD-NT also localizes to mitochondria causing dysfunction; GSDMD expression is transcriptionally driven by IRF2 binding a unique promoter element; and GSDMD activity is further regulated by post-translational modifications including acetylation (at K248, reversed by HDAC4), K33-linked ubiquitination (at K51 by TRIM21, targeting it for autophagic degradation), and O-GlcNAcylation (at S338, blocking caspase-4 interaction)."},"narrative":{"mechanistic_narrative":"GSDMD is the terminal pore-forming executioner of pyroptosis, an inflammatory programmed cell death triggered by inflammatory caspase activation [PMID:26375003]. In its resting state GSDMD is autoinhibited: the first loop of the C-terminal gasdermin-C domain inserts into the N-terminal gasdermin-N domain, masking a positively charged oligomerization surface; inflammatory caspases-1, -4, -5, and -11 cleave the interdomain linker to liberate GSDMD-NT, which is both necessary and sufficient to kill the cell [PMID:26375003, PMID:28928145]. Caspase recognition occurs through a conserved hydrophobic interface on GSDMD-C engaged by the autoprocessed caspase p10 fragment, allowing cleavage independently of the canonical tetrapeptide site [PMID:32109412]. Freed GSDMD-NT inserts into the plasma membrane as monomers and then oligomerizes into large pores, a temporal order resolved by intracellular nanobodies that block oligomerization without preventing membrane insertion [PMID:39327452]; this trafficking is gated by a palmitoylation cycle in which DHHC7 palmitoylates C192 and APT2 subsequently depalmitoylates it to license oligomerization [PMID:38538834]. The resulting pores drive pyroptotic lysis, IL-1β/IL-18 release, and calcium influx, the last of which recruits the ESCRT-III machinery (CHMP4B, VPS4A) to repair damaged membrane and antagonize pyroptosis [PMID:30467171, PMID:37931722]. GSDMD operates across canonical (NLRP3, NLRC4, NLRP1b, Pyrin, AIM2) and noncanonical inflammasome platforms and also lies downstream of caspase-8 in a FADD-restrained epithelial death pathway [PMID:35899491, PMID:32362323]. GSDMD-NT additionally localizes to mitochondria, causing aggregation, oxidative stress, and mtDNA leakage that activates STING/cGAS signaling [PMID:40067887, PMID:38695170]. Expression is controlled transcriptionally by IRF2 binding a unique promoter element [PMID:31113851], and GSDMD activity is further tuned by acetylation at K248 (reversed by HDAC4), K33-linked ubiquitination at K51 by TRIM21 directing p62-mediated autophagic degradation, and O-GlcNAcylation at S338 that blocks caspase engagement [PMID:38326336, PMID:39824372, PMID:37962578]. GSDMD can also be activated pharmacologically without cleavage, and its pore can be blocked by small molecules and covalent cysteine modifiers, establishing it as a therapeutic target in sepsis, ischemia/reperfusion, and tumor immunity [PMID:39243763, PMID:37782407, PMID:39848475].","teleology":[{"year":2015,"claim":"Established GSDMD as the essential effector of pyroptosis, answering what links inflammatory caspase activation to inflammatory cell death and cytokine release.","evidence":"Genome-wide CRISPR screen in mouse macrophages with GSDMD knockout and domain-mapping constructs","pmids":["26375003"],"confidence":"High","gaps":["Structural basis of autoinhibition not yet defined","Mechanism of membrane pore assembly unknown","Caspase recognition mode not resolved"]},{"year":2017,"claim":"Resolved the structural logic of autoinhibition and oligomerization, explaining how cleavage converts a dormant protein into a membrane-disrupting effector.","evidence":"Crystal structure of GSDMD-C, SAXS of full-length GSDMD, and mutagenesis with cell-death and bactericidal assays","pmids":["28928145"],"confidence":"High","gaps":["Pore architecture in the membrane not visualized","Order of membrane insertion vs oligomerization unresolved"]},{"year":2018,"claim":"Identified a cell-intrinsic brake on pyroptosis, showing pore-induced calcium influx triggers ESCRT-III membrane repair to limit cell death.","evidence":"Live-cell calcium imaging with genetic and pharmacological ESCRT-III inhibition in human and murine macrophages","pmids":["30467171"],"confidence":"High","gaps":["Direct physical link between GSDMD pores and ESCRT recruitment not defined here","Stoichiometry of repair vs pore formation unknown"]},{"year":2019,"claim":"Defined transcriptional control of GSDMD, showing IRF2 sets the cellular threshold for inflammasome competence.","evidence":"ENU mutagenesis screen, IRF2 knockout cells/tissues, and promoter binding assays","pmids":["31113851"],"confidence":"High","gaps":["Signals upstream of IRF2 not defined","Other transcriptional regulators not excluded"]},{"year":2020,"claim":"Explained how caspases recognize GSDMD independently of a tetrapeptide motif, identifying a conserved C-domain hydrophobic interface engaged by autoprocessed caspase p10.","evidence":"Crystal structures of caspase-4/11- and caspase-1-GSDMD-C complexes with biochemical and cellular validation","pmids":["32109412"],"confidence":"High","gaps":["Whether all caspases use identical interface kinetics unclear","Regulation of caspase-GSDMD docking in cells not addressed"]},{"year":2020,"claim":"Positioned GSDMD downstream of caspase-8 in a FADD-restrained epithelial death pathway distinct from necroptosis, broadening its pathway context beyond inflammatory caspases.","evidence":"Genetic epistasis with IEC-specific FADD, caspase-8, MLKL, and GSDMD knockout combinations in mice","pmids":["32362323"],"confidence":"High","gaps":["Direct caspase-8 cleavage of GSDMD not biochemically shown here","Tissue specificity of this pathway unclear"]},{"year":2022,"claim":"Delineated GSDMD's role across inflammasome platforms in neutrophils and dissociated it from NETosis, clarifying which neutrophil functions depend on GSDMD.","evidence":"GSDMD-knockout neutrophils with multiple canonical inflammasome activators and PMA-NETosis assays","pmids":["35899491"],"confidence":"High","gaps":["Conditions under which GSDMD contributes to NETs remained unresolved","Neutrophil-specific pore dynamics not measured"]},{"year":2024,"claim":"Identified a palmitoylation/depalmitoylation cycle (DHHC7, APT2) at C192 that gates GSDMD trafficking and pore assembly, adding a lipid-modification checkpoint to activation.","evidence":"Acyl-RAC assays, C192 mutagenesis, DHHC7/APT2 perturbation, and in vivo LPS sepsis models","pmids":["38538834"],"confidence":"High","gaps":["Spatial coordination of palmitoylation cycle with caspase cleavage unclear","Whether the cycle applies to all activation routes unknown"]},{"year":2024,"claim":"Resolved the kinetic order of pore formation, showing GSDMD-NT inserts as monomers before oligomerizing, and that blocking oligomerization reroutes death to apoptosis.","evidence":"Intracellular and extracellular nanobodies with membrane partitioning and caspase activity readouts","pmids":["39327452"],"confidence":"High","gaps":["Structure of the inserted monomer intermediate not determined","In vivo relevance of pyroptosis-to-apoptosis switch not tested"]},{"year":2024,"claim":"Demonstrated GSDMD pores can be activated pharmacologically without cleavage and exploited for antitumor immunity, decoupling pore formation from proteolytic processing.","evidence":"High-throughput chemical screen identifying DMB with liposome leakage and tumor models","pmids":["39243763"],"confidence":"High","gaps":["Mechanism by which DMB bypasses autoinhibition not fully defined","Selectivity over other gasdermins not detailed here"]},{"year":2024,"claim":"Established GSDMD-NT mitochondrial localization as a direct driver of organelle dysfunction and oxidative stress, expanding pore action beyond the plasma membrane.","evidence":"Gsdmd-KO mice, pharmacological inhibition, and microscopy/ROS assays in cochlear cells","pmids":["40067887"],"confidence":"High","gaps":["Targeting signal directing GSDMD-NT to mitochondria unknown","Relative contribution of mitochondrial vs plasma membrane pores unresolved"]},{"year":2024,"claim":"Mapped post-transcriptional and post-translational control nodes (acetylation/HDAC4, K33-ubiquitination/TRIM21-p62, O-GlcNAcylation, m6A, 2'-O-methylation) that tune GSDMD abundance and activation.","evidence":"Mass spectrometry, site-directed mutagenesis, writer/eraser/reader identification, and RNA-modification assays across multiple disease models","pmids":["38326336","39824372","37962578","39627574","39450788"],"confidence":"Medium","gaps":["Cross-talk and hierarchy among modifications not established","Most are single-lab findings without independent replication","Physiological contexts in which each modification dominates unclear"]},{"year":2024,"claim":"Connected GSDMD to context-dependent disease outcomes via mtDNA-STING signaling, cytokine-driven tissue damage, and intercellular transfer of GSDMD-N-bearing mitochondria.","evidence":"Tissue-specific KO/knockdown mice in atherosclerosis, sepsis, and ischemia/reperfusion with pathway and microvesicle transfer assays","pmids":["38695170","37794018","38169726","39227368","35783187","36906959","38632402"],"confidence":"Medium","gaps":["Direct biochemical mechanism of intercellular GSDMD transfer not fully resolved","Acute vs chronic dual roles of GSDMD remain context-dependent","Many findings are single-lab disease-model studies"]},{"year":null,"claim":"A unified structural model of the assembled GSDMD membrane pore, the determinants of mitochondrial versus plasma-membrane targeting, and the integration of competing PTM checkpoints into a single regulatory logic remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of the assembled pore in the timeline","Mechanism selecting mitochondrial vs plasma membrane localization unknown","Hierarchy among transcriptional, RNA, and protein modifications unestablished"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[1,9]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,1,7]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[5,7,24]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[15,21]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,4,17]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[3,21]}],"complexes":[],"partners":["CASP1","CASP4","CASP11","DHHC7","APT2","TRIM21","CHMP4B","VPS4A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P57764","full_name":"Gasdermin-D","aliases":["Gasdermin domain-containing protein 1"],"length_aa":484,"mass_kda":52.8,"function":"Precursor of a pore-forming protein that plays a key role in host defense against pathogen infection and danger signals (PubMed:26375003, PubMed:26375259, PubMed:27281216). This form constitutes the precursor of the pore-forming protein: upon cleavage, the released N-terminal moiety (Gasdermin-D, N-terminal) binds to membranes and forms pores, triggering pyroptosis (PubMed:26375003, PubMed:26375259, PubMed:27281216) Promotes pyroptosis in response to microbial infection and danger signals (PubMed:26375003, PubMed:26375259, PubMed:27418190, PubMed:28392147, PubMed:32820063, PubMed:34289345, PubMed:38040708, PubMed:38530158, PubMed:38599239). Produced by the cleavage of gasdermin-D by inflammatory caspases CASP1, CASP4 or CASP5 in response to canonical, as well as non-canonical (such as cytosolic LPS) inflammasome activators (PubMed:26375003, PubMed:26375259, PubMed:27418190). After cleavage, moves to the plasma membrane where it strongly binds to inner leaflet lipids, including monophosphorylated phosphatidylinositols, such as phosphatidylinositol 4-phosphate, bisphosphorylated phosphatidylinositols, such as phosphatidylinositol (4,5)-bisphosphate, as well as phosphatidylinositol (3,4,5)-bisphosphate, and more weakly to phosphatidic acid and phosphatidylserine (PubMed:27281216, PubMed:29898893, PubMed:36227980). Homooligomerizes within the membrane and forms pores of 10-15 nanometers (nm) of inner diameter, allowing the release of mature interleukin-1 (IL1B and IL18) and triggering pyroptosis (PubMed:27281216, PubMed:27418190, PubMed:29898893, PubMed:33883744, PubMed:38040708, PubMed:38530158, PubMed:38599239). Gasdermin pores also allow the release of mature caspase-7 (CASP7) (By similarity). In some, but not all, cells types, pyroptosis is followed by pyroptotic cell death, which is caused by downstream activation of ninjurin-1 (NINJ1), which mediates membrane rupture (cytolysis) (PubMed:33472215, PubMed:37198476). Also forms pores in the mitochondrial membrane, resulting in release of mitochondrial DNA (mtDNA) into the cytosol (By similarity). Gasdermin-D, N-terminal released from pyroptotic cells into the extracellular milieu rapidly binds to and kills both Gram-negative and Gram-positive bacteria, without harming neighboring mammalian cells, as it does not disrupt the plasma membrane from the outside due to lipid-binding specificity (PubMed:27281216). Under cell culture conditions, also active against intracellular bacteria, such as Listeria monocytogenes (By similarity). Also active in response to MAP3K7/TAK1 inactivation by Yersinia toxin YopJ, which triggers cleavage by CASP8 and subsequent activation (By similarity). Required for mucosal tissue defense against enteric pathogens (By similarity). Activation of the non-canonical inflammasome in brain endothelial cells can lead to excessive pyroptosis, leading to blood-brain barrier breakdown (By similarity). Strongly binds to bacterial and mitochondrial lipids, including cardiolipin (PubMed:27281216). Does not bind to unphosphorylated phosphatidylinositol, phosphatidylethanolamine nor phosphatidylcholine (PubMed:27281216) Transcription coactivator produced by the cleavage by CASP3 or CASP7 in the upper small intestine in response to dietary antigens (By similarity). Required to maintain food tolerance in small intestine: translocates to the nucleus and acts as a coactivator for STAT1 to induce the transcription of CIITA and MHC class II molecules, which in turn induce type 1 regulatory T (Tr1) cells in upper small intestine (By similarity) Produced by the cleavage by papain allergen (PubMed:35794369). After cleavage, moves to the plasma membrane and homooligomerizes within the membrane and forms pores of 10-15 nanometers (nm) of inner diameter, allowing the specific release of mature interleukin-33 (IL33), promoting type 2 inflammatory immune response (PubMed:35794369)","subcellular_location":"Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/P57764/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GSDMD","classification":"Not Classified","n_dependent_lines":54,"n_total_lines":1208,"dependency_fraction":0.04470198675496689},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GSDMD","total_profiled":1310},"omim":[{"mim_id":"620795","title":"AUTOINFLAMMATION WITH EPISODIC FEVER AND IMMUNE DYSREGULATION; AIFID","url":"https://www.omim.org/entry/620795"},{"mim_id":"620331","title":"HATIPOGLU IMMUNODEFICIENCY SYNDROME; HATIS","url":"https://www.omim.org/entry/620331"},{"mim_id":"618755","title":"SHORT TRANSMEMBRANE MITOCHONDRIAL PROTEIN 1; STMP1","url":"https://www.omim.org/entry/618755"},{"mim_id":"617042","title":"GASDERMIN D; GSDMD","url":"https://www.omim.org/entry/617042"},{"mim_id":"611885","title":"SHANK-ASSOCIATED RH DOMAIN INTERACTOR; SHARPIN","url":"https://www.omim.org/entry/611885"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GSDMD"},"hgnc":{"alias_symbol":["FLJ12150","DF5L"],"prev_symbol":["GSDMDC1"]},"alphafold":{"accession":"P57764","domains":[{"cath_id":"-","chopping":"5-93_111-178_206-231","consensus_level":"high","plddt":85.6171,"start":5,"end":231},{"cath_id":"-","chopping":"286-484","consensus_level":"medium","plddt":85.4627,"start":286,"end":484}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P57764","model_url":"https://alphafold.ebi.ac.uk/files/AF-P57764-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P57764-F1-predicted_aligned_error_v6.png","plddt_mean":77.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GSDMD","jax_strain_url":"https://www.jax.org/strain/search?query=GSDMD"},"sequence":{"accession":"P57764","fasta_url":"https://rest.uniprot.org/uniprotkb/P57764.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P57764/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P57764"}},"corpus_meta":[{"pmid":"26375003","id":"PMC_26375003","title":"Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26375003","citation_count":5373,"is_preprint":false},{"pmid":"32109412","id":"PMC_32109412","title":"Structural Mechanism for GSDMD Targeting by Autoprocessed Caspases in Pyroptosis.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32109412","citation_count":599,"is_preprint":false},{"pmid":"30467171","id":"PMC_30467171","title":"ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation.","date":"2018","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30467171","citation_count":597,"is_preprint":false},{"pmid":"34877938","id":"PMC_34877938","title":"NLRP3/caspase-1/GSDMD-mediated pyroptosis exerts a crucial role in astrocyte pathological injury in mouse model of depression.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/34877938","citation_count":290,"is_preprint":false},{"pmid":"34015941","id":"PMC_34015941","title":"GSDMD-Mediated Cardiomyocyte Pyroptosis Promotes Myocardial I/R Injury.","date":"2021","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/34015941","citation_count":288,"is_preprint":false},{"pmid":"32330868","id":"PMC_32330868","title":"Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway.","date":"2020","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/32330868","citation_count":287,"is_preprint":false},{"pmid":"34326697","id":"PMC_34326697","title":"Cisplatin Induces Pyroptosis via Activation of MEG3/NLRP3/caspase-1/GSDMD Pathway in Triple-Negative Breast Cancer.","date":"2021","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34326697","citation_count":251,"is_preprint":false},{"pmid":"35714743","id":"PMC_35714743","title":"Polystyrene microplastics-induced cardiotoxicity in chickens via the ROS-driven NF-κB-NLRP3-GSDMD and AMPK-PGC-1α axes.","date":"2022","source":"The Science of the total environment","url":"https://pubmed.ncbi.nlm.nih.gov/35714743","citation_count":238,"is_preprint":false},{"pmid":"32362323","id":"PMC_32362323","title":"FADD and Caspase-8 Regulate Gut Homeostasis and Inflammation by Controlling MLKL- and GSDMD-Mediated Death of Intestinal Epithelial Cells.","date":"2020","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/32362323","citation_count":234,"is_preprint":false},{"pmid":"28928145","id":"PMC_28928145","title":"Structure insight of GSDMD reveals the basis of GSDMD autoinhibition in cell pyroptosis.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28928145","citation_count":232,"is_preprint":false},{"pmid":"38632402","id":"PMC_38632402","title":"Brain endothelial GSDMD activation mediates inflammatory BBB breakdown.","date":"2024","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/38632402","citation_count":214,"is_preprint":false},{"pmid":"31113851","id":"PMC_31113851","title":"IRF2 transcriptionally induces GSDMD expression for pyroptosis.","date":"2019","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/31113851","citation_count":154,"is_preprint":false},{"pmid":"35279683","id":"PMC_35279683","title":"HDAC11 promotes both NLRP3/caspase-1/GSDMD and caspase-3/GSDME pathways causing pyroptosis via ERG in vascular endothelial cells.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35279683","citation_count":133,"is_preprint":false},{"pmid":"38538834","id":"PMC_38538834","title":"A palmitoylation-depalmitoylation relay spatiotemporally controls GSDMD activation in pyroptosis.","date":"2024","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/38538834","citation_count":115,"is_preprint":false},{"pmid":"35941120","id":"PMC_35941120","title":"GSDMD-dependent neutrophil extracellular traps promote macrophage-to-myofibroblast transition and renal fibrosis in obstructive nephropathy.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35941120","citation_count":114,"is_preprint":false},{"pmid":"33871879","id":"PMC_33871879","title":"Acinar cell NLRP3 inflammasome and gasdermin D (GSDMD) activation mediates pyroptosis and systemic inflammation in acute pancreatitis.","date":"2021","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33871879","citation_count":107,"is_preprint":false},{"pmid":"35770948","id":"PMC_35770948","title":"Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway.","date":"2022","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/35770948","citation_count":100,"is_preprint":false},{"pmid":"34795266","id":"PMC_34795266","title":"Inflammasome-mediated GSDMD activation facilitates escape of Candida albicans from macrophages.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34795266","citation_count":85,"is_preprint":false},{"pmid":"34955116","id":"PMC_34955116","title":"GSDMD-mediated pyroptosis: a critical mechanism of diabetic nephropathy.","date":"2021","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34955116","citation_count":84,"is_preprint":false},{"pmid":"34537816","id":"PMC_34537816","title":"Trimetazidine attenuates dexamethasone-induced muscle atrophy via inhibiting NLRP3/GSDMD pathway-mediated pyroptosis.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34537816","citation_count":82,"is_preprint":false},{"pmid":"35154128","id":"PMC_35154128","title":"Didymin Suppresses Microglia Pyroptosis and Neuroinflammation Through the Asc/Caspase-1/GSDMD Pathway Following Experimental Intracerebral Hemorrhage.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35154128","citation_count":82,"is_preprint":false},{"pmid":"35774778","id":"PMC_35774778","title":"The Regulation and Modification of GSDMD Signaling in Diseases.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35774778","citation_count":81,"is_preprint":false},{"pmid":"39243763","id":"PMC_39243763","title":"Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/39243763","citation_count":77,"is_preprint":false},{"pmid":"35899491","id":"PMC_35899491","title":"GSDMD drives canonical inflammasome-induced neutrophil pyroptosis and is dispensable for NETosis.","date":"2022","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/35899491","citation_count":75,"is_preprint":false},{"pmid":"37834220","id":"PMC_37834220","title":"Ursolic Acid Alleviates Neuroinflammation after Intracerebral Hemorrhage by Mediating Microglial Pyroptosis via the NF-κB/NLRP3/GSDMD Pathway.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37834220","citation_count":68,"is_preprint":false},{"pmid":"33587329","id":"PMC_33587329","title":"Pyroptosis executive protein GSDMD as a biomarker for diagnosis and identification of Alzheimer's disease.","date":"2021","source":"Brain and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/33587329","citation_count":68,"is_preprint":false},{"pmid":"38169726","id":"PMC_38169726","title":"Pyroptotic Macrophage-Derived Microvesicles Accelerate Formation of Neutrophil Extracellular Traps via GSDMD-N-expressing Mitochondrial Transfer during Sepsis.","date":"2024","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38169726","citation_count":66,"is_preprint":false},{"pmid":"35228524","id":"PMC_35228524","title":"Myoglobin promotes macrophage polarization to M1 type and pyroptosis via the RIG-I/Caspase1/GSDMD signaling pathway in CS-AKI.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35228524","citation_count":66,"is_preprint":false},{"pmid":"35688553","id":"PMC_35688553","title":"Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35688553","citation_count":63,"is_preprint":false},{"pmid":"36635060","id":"PMC_36635060","title":"Efficient Delivery of GSDMD-N mRNA by Engineered Extracellular Vesicles Induces Pyroptosis for Enhanced Immunotherapy.","date":"2023","source":"Small (Weinheim an der Bergstrasse, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36635060","citation_count":63,"is_preprint":false},{"pmid":"38695170","id":"PMC_38695170","title":"Macrophage-Derived GSDMD Plays an Essential Role in Atherosclerosis and Cross Talk Between Macrophages via the Mitochondria-STING-IRF3/NF-κB Axis.","date":"2024","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38695170","citation_count":60,"is_preprint":false},{"pmid":"37864196","id":"PMC_37864196","title":"ERRα promotes glycolytic metabolism and targets the NLRP3/caspase-1/GSDMD pathway to regulate pyroptosis in endometrial cancer.","date":"2023","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/37864196","citation_count":57,"is_preprint":false},{"pmid":"37974278","id":"PMC_37974278","title":"Simvastatin induces pyroptosis via ROS/caspase-1/GSDMD pathway in colon cancer.","date":"2023","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/37974278","citation_count":54,"is_preprint":false},{"pmid":"37794018","id":"PMC_37794018","title":"GSDMD promotes neutrophil extracellular traps via mtDNA-cGAS-STING pathway during lung ischemia/reperfusion.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37794018","citation_count":52,"is_preprint":false},{"pmid":"38804602","id":"PMC_38804602","title":"Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer.","date":"2024","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38804602","citation_count":51,"is_preprint":false},{"pmid":"31191857","id":"PMC_31191857","title":"Gasdermin D (GSDMD) as a new target for the treatment of infection.","date":"2019","source":"MedChemComm","url":"https://pubmed.ncbi.nlm.nih.gov/31191857","citation_count":47,"is_preprint":false},{"pmid":"34212273","id":"PMC_34212273","title":"Hirudin ameliorates diabetic nephropathy by inhibiting Gsdmd-mediated pyroptosis.","date":"2021","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/34212273","citation_count":46,"is_preprint":false},{"pmid":"38552923","id":"PMC_38552923","title":"Pyroptosis-mediator GSDMD promotes Parkinson's disease pathology via microglial activation and dopaminergic neuronal death.","date":"2024","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/38552923","citation_count":45,"is_preprint":false},{"pmid":"37685976","id":"PMC_37685976","title":"Puerarin Inhibits NLRP3-Caspase-1-GSDMD-Mediated Pyroptosis via P2X7 Receptor in Cardiomyocytes and Macrophages.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37685976","citation_count":44,"is_preprint":false},{"pmid":"37782407","id":"PMC_37782407","title":"Novel GSDMD inhibitor GI-Y1 protects heart against pyroptosis and ischemia/reperfusion injury by blocking pyroptotic pore formation.","date":"2023","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/37782407","citation_count":41,"is_preprint":false},{"pmid":"32187511","id":"PMC_32187511","title":"Mitochondrial GSDMD Pores DAMPen Pyroptosis.","date":"2020","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/32187511","citation_count":38,"is_preprint":false},{"pmid":"35969260","id":"PMC_35969260","title":"Review: the role of GSDMD in sepsis.","date":"2022","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/35969260","citation_count":35,"is_preprint":false},{"pmid":"35439536","id":"PMC_35439536","title":"Involvement of NLRP3/Caspase-1/GSDMD-Dependent pyroptosis in BPA-Induced apoptosis of human neuroblastoma cells.","date":"2022","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35439536","citation_count":34,"is_preprint":false},{"pmid":"36690641","id":"PMC_36690641","title":"Hepatic TNFRSF12A promotes bile acid-induced hepatocyte pyroptosis through NFκB/Caspase-1/GSDMD signaling in cholestasis.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36690641","citation_count":33,"is_preprint":false},{"pmid":"39994107","id":"PMC_39994107","title":"GSDMD-mediated pyroptosis: molecular mechanisms, diseases and therapeutic targets.","date":"2025","source":"Molecular biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/39994107","citation_count":32,"is_preprint":false},{"pmid":"39479449","id":"PMC_39479449","title":"Targeting the smooth muscle cell Keap1-Nrf2-GSDMD-pyroptosis axis by cryptotanshinone prevents abdominal aortic aneurysm formation.","date":"2024","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/39479449","citation_count":31,"is_preprint":false},{"pmid":"37056920","id":"PMC_37056920","title":"PD-L1 promotes GSDMD-mediated NET release by maintaining the transcriptional activity of Stat3 in sepsis-associated encephalopathy.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37056920","citation_count":30,"is_preprint":false},{"pmid":"37063846","id":"PMC_37063846","title":"LDC7559 inhibits microglial activation and GSDMD-dependent pyroptosis after subarachnoid hemorrhage.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37063846","citation_count":30,"is_preprint":false},{"pmid":"36217543","id":"PMC_36217543","title":"GSDMD contributes to myocardial reperfusion injury by regulating pyroptosis.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36217543","citation_count":30,"is_preprint":false},{"pmid":"35669106","id":"PMC_35669106","title":"Ablation of GSDMD Attenuates Neurological Deficits and Neuropathological Alterations After Traumatic Brain Injury.","date":"2022","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35669106","citation_count":28,"is_preprint":false},{"pmid":"36421808","id":"PMC_36421808","title":"Oridonin Protects against Myocardial Ischemia-Reperfusion Injury by Inhibiting GSDMD-Mediated Pyroptosis.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36421808","citation_count":27,"is_preprint":false},{"pmid":"39327452","id":"PMC_39327452","title":"Antagonistic nanobodies implicate mechanism of GSDMD pore formation and potential therapeutic application.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39327452","citation_count":26,"is_preprint":false},{"pmid":"38548966","id":"PMC_38548966","title":"Targeting STING elicits GSDMD-dependent pyroptosis and boosts anti-tumor immunity in renal cell carcinoma.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/38548966","citation_count":26,"is_preprint":false},{"pmid":"36893672","id":"PMC_36893672","title":"Anti-inflammatory effect of Danhong injection through inhibition of GSDMD-mediated pyroptosis.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36893672","citation_count":26,"is_preprint":false},{"pmid":"36459518","id":"PMC_36459518","title":"Blocking Caspase-1/Gsdmd and Caspase-3/-8/Gsdme pyroptotic pathways rescues silicosis in mice.","date":"2022","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36459518","citation_count":25,"is_preprint":false},{"pmid":"38436813","id":"PMC_38436813","title":"Caspase-11/GSDMD contributes to the progression of hyperuricemic nephropathy by promoting NETs formation.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38436813","citation_count":24,"is_preprint":false},{"pmid":"38844113","id":"PMC_38844113","title":"Lipocalin-2-mediated intestinal epithelial cells pyroptosis via NF-κB/NLRP3/GSDMD signaling axis adversely affects inflammation in colitis.","date":"2024","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/38844113","citation_count":23,"is_preprint":false},{"pmid":"38993566","id":"PMC_38993566","title":"P2X7R Modulates NEK7-NLRP3 Interaction to Exacerbate Experimental Autoimmune Prostatitis via GSDMD-mediated Prostate Epithelial Cell Pyroptosis.","date":"2024","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38993566","citation_count":21,"is_preprint":false},{"pmid":"36068399","id":"PMC_36068399","title":"GSDMD-mediated pyroptosis in retinal vascular inflammatory diseases: a review.","date":"2022","source":"International ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/36068399","citation_count":21,"is_preprint":false},{"pmid":"36599874","id":"PMC_36599874","title":"GSDMD deficiency ameliorates hyperoxia-induced BPD and ROP in neonatal mice.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36599874","citation_count":20,"is_preprint":false},{"pmid":"37717911","id":"PMC_37717911","title":"Enteric fungi protect against intestinal ischemia-reperfusion injury via inhibiting the SAA1-GSDMD pathway.","date":"2023","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/37717911","citation_count":19,"is_preprint":false},{"pmid":"36224321","id":"PMC_36224321","title":"mTORC1-Dependent and GSDMD-Mediated Pyroptosis in Developmental Sevoflurane Neurotoxicity.","date":"2022","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36224321","citation_count":19,"is_preprint":false},{"pmid":"38262162","id":"PMC_38262162","title":"Macrophage-derived GSDMD promotes abdominal aortic aneurysm and aortic smooth muscle cells pyroptosis.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38262162","citation_count":17,"is_preprint":false},{"pmid":"36517743","id":"PMC_36517743","title":"Ceramide induces pyroptosis through TXNIP/NLRP3/GSDMD pathway in HUVECs.","date":"2022","source":"BMC molecular and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36517743","citation_count":17,"is_preprint":false},{"pmid":"39069522","id":"PMC_39069522","title":"EZH2-STAT3 signaling pathway regulates GSDMD-mediated pyroptosis in glioblastoma.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/39069522","citation_count":17,"is_preprint":false},{"pmid":"37962578","id":"PMC_37962578","title":"O-GlcNAc modification of GSDMD attenuates LPS-induced endothelial cells pyroptosis.","date":"2023","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/37962578","citation_count":17,"is_preprint":false},{"pmid":"39255724","id":"PMC_39255724","title":"Paeoniflorin inhibited GSDMD to alleviate ANIT-induced cholestasis via pyroptosis signaling pathway.","date":"2024","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39255724","citation_count":16,"is_preprint":false},{"pmid":"38326336","id":"PMC_38326336","title":"Crosstalk of HDAC4, PP1, and GSDMD in controlling pyroptosis.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38326336","citation_count":16,"is_preprint":false},{"pmid":"39127315","id":"PMC_39127315","title":"Igniting hope: Harnessing NLRP3 inflammasome-GSDMD-mediated pyroptosis for cancer immunotherapy.","date":"2024","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39127315","citation_count":14,"is_preprint":false},{"pmid":"39859234","id":"PMC_39859234","title":"HERV-W Env Induces Neuron Pyroptosis via the NLRP3-CASP1-GSDMD Pathway in Recent-Onset Schizophrenia.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39859234","citation_count":14,"is_preprint":false},{"pmid":"37931722","id":"PMC_37931722","title":"CHMP4B and VSP4A reverse GSDMD-mediated pyroptosis by cell membrane remodeling in endometrial carcinoma.","date":"2023","source":"Biochimica et biophysica acta. General subjects","url":"https://pubmed.ncbi.nlm.nih.gov/37931722","citation_count":13,"is_preprint":false},{"pmid":"35783187","id":"PMC_35783187","title":"Inhibition of GSDMD Activates Poly(ADP-ribosyl)ation and Promotes Myocardial Ischemia-Reperfusion Injury.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/35783187","citation_count":13,"is_preprint":false},{"pmid":"40028157","id":"PMC_40028157","title":"Cordycepin attenuates NLRP3/Caspase-1/GSDMD-mediated LPS-induced macrophage pyroptosis.","date":"2025","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40028157","citation_count":12,"is_preprint":false},{"pmid":"37679766","id":"PMC_37679766","title":"GSDMD gene knockout alleviates hyperoxia-induced hippocampal brain injury in neonatal mice.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37679766","citation_count":12,"is_preprint":false},{"pmid":"37830762","id":"PMC_37830762","title":"ELP2-NLRP3-GSDMD/GSDME-mediated pyroptosis is induced by TNF-α in MC3T3-E1 cells during osteogenic differentiation.","date":"2023","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37830762","citation_count":12,"is_preprint":false},{"pmid":"39201786","id":"PMC_39201786","title":"GSDMD-Dependent Neutrophil Extracellular Traps Mediate Portal Vein Thrombosis and Associated Fibrosis in Cirrhosis.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39201786","citation_count":11,"is_preprint":false},{"pmid":"40018871","id":"PMC_40018871","title":"Inhibition of Caspase-1 Suppresses GSDMD-mediated Peritoneal Mesothelial Cell Pyroptosis and Inflammation in Peritoneal Fibrosis.","date":"2025","source":"Small (Weinheim an der Bergstrasse, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40018871","citation_count":11,"is_preprint":false},{"pmid":"36328986","id":"PMC_36328986","title":"Obeticholic acid improved triptolide/lipopolysaccharide-induced hepatotoxicity by inhibiting caspase-11-GSDMD pyroptosis pathway.","date":"2022","source":"Journal of applied toxicology : JAT","url":"https://pubmed.ncbi.nlm.nih.gov/36328986","citation_count":11,"is_preprint":false},{"pmid":"36906959","id":"PMC_36906959","title":"GSDMD-mediated pyroptosis promotes cardiac remodeling in pressure overload.","date":"2023","source":"Clinical and experimental hypertension (New York, N.Y. : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/36906959","citation_count":11,"is_preprint":false},{"pmid":"36691613","id":"PMC_36691613","title":"PKR deficiency delays vascular aging via inhibiting GSDMD-mediated endothelial cell hyperactivation.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/36691613","citation_count":11,"is_preprint":false},{"pmid":"40726432","id":"PMC_40726432","title":"Ligilactobacillus Murinus and Lactobacillus Johnsonii Suppress Macrophage Pyroptosis in Atherosclerosis through Butyrate-GPR109A-GSDMD Axis.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40726432","citation_count":10,"is_preprint":false},{"pmid":"39227368","id":"PMC_39227368","title":"GSDMD KNOCKOUT ALLEVIATES SEPSIS-ASSOCIATED SKELETAL MUSCLE ATROPHY BY INHIBITING IL18/AMPK SIGNALING.","date":"2024","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/39227368","citation_count":10,"is_preprint":false},{"pmid":"38898209","id":"PMC_38898209","title":"Gut microbiota-mediated activation of GSDMD ignites colorectal tumorigenesis.","date":"2024","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38898209","citation_count":10,"is_preprint":false},{"pmid":"38977508","id":"PMC_38977508","title":"Targeting BRD4 mitigates hepatocellular lipotoxicity by suppressing the NLRP3 inflammasome activation and GSDMD-mediated hepatocyte pyroptosis.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38977508","citation_count":9,"is_preprint":false},{"pmid":"39725843","id":"PMC_39725843","title":"Rhaponticin Alleviates Collagen-induced Arthritis by Inhibiting NLRP3/GSDMD-mediated Neutrophil Extracellular Traps.","date":"2024","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/39725843","citation_count":9,"is_preprint":false},{"pmid":"39777764","id":"PMC_39777764","title":"Sepsis-induced NET formation requires MYD88 but is independent of GSDMD and PAD4.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/39777764","citation_count":9,"is_preprint":false},{"pmid":"38319525","id":"PMC_38319525","title":"Hydroxysafflor Yellow A Inhibits Pyroptosis and Protecting HUVECs from OGD/R via NLRP3/Caspase-1/GSDMD Pathway.","date":"2024","source":"Chinese journal of integrative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38319525","citation_count":9,"is_preprint":false},{"pmid":"37676465","id":"PMC_37676465","title":"PIK3CG Regulates NLRP3/GSDMD-Mediated Pyroptosis in Septic Myocardial Injury.","date":"2023","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37676465","citation_count":9,"is_preprint":false},{"pmid":"34994274","id":"PMC_34994274","title":"Pulsed electromagnetic field alleviates synovitis and inhibits the NLRP3/Caspase-1/GSDMD signaling pathway in osteoarthritis rats.","date":"2022","source":"Electromagnetic biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34994274","citation_count":9,"is_preprint":false},{"pmid":"39450788","id":"PMC_39450788","title":"SNORD99 promotes endometrial cancer development by inhibiting GSDMD-mediated pyroptosis through 2'-O-methylation modification.","date":"2024","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39450788","citation_count":9,"is_preprint":false},{"pmid":"37357358","id":"PMC_37357358","title":"Palmitic acid induces GSDMD-mediated pyroptosis in periodontal ligament cells via the NF-κB pathway.","date":"2023","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/37357358","citation_count":9,"is_preprint":false},{"pmid":"39831511","id":"PMC_39831511","title":"TRAF6 promotes abdominal aortic aneurysm development by activating macrophage pyroptosis via the NLRP3/Caspase1/GSDMD pathway.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/39831511","citation_count":8,"is_preprint":false},{"pmid":"40067887","id":"PMC_40067887","title":"GSDMD-mediated mitochondrial dysfunction in marginal cells: A potential driver of inflammation and stria vascularis damage in CIHL.","date":"2025","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/40067887","citation_count":8,"is_preprint":false},{"pmid":"39696607","id":"PMC_39696607","title":"Astragaloside IV attenuates podocyte apoptosis via regulating TXNIP/NLRP3/GSDMD signaling pathway in diabetic nephropathy.","date":"2024","source":"Diabetology & metabolic syndrome","url":"https://pubmed.ncbi.nlm.nih.gov/39696607","citation_count":8,"is_preprint":false},{"pmid":"39334337","id":"PMC_39334337","title":"RACK1 and NEK7 mediate GSDMD-dependent macrophage pyroptosis upon Streptococcus suis infection.","date":"2024","source":"Veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/39334337","citation_count":8,"is_preprint":false},{"pmid":"39627574","id":"PMC_39627574","title":"The N6-methyladenosine writer METTL3 promotes breast cancer progression through YTHDF2-dependent posttranscriptional silencing of GSDMD.","date":"2024","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/39627574","citation_count":8,"is_preprint":false},{"pmid":"39848475","id":"PMC_39848475","title":"Targeting GSDMD JX06 inhibits PANoptosis and multiple organ injury.","date":"2025","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39848475","citation_count":8,"is_preprint":false},{"pmid":"39824372","id":"PMC_39824372","title":"Scutellarin inhibits pyroptosis via selective autophagy degradation of p30/GSDMD and suppression of ASC oligomerization.","date":"2025","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/39824372","citation_count":8,"is_preprint":false},{"pmid":"36057231","id":"PMC_36057231","title":"Macrophages promote growth, migration and epithelial-mesenchymal transition of renal cell carcinoma by regulating GSDMD/IL-1β axis.","date":"2022","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/36057231","citation_count":8,"is_preprint":false},{"pmid":"38532477","id":"PMC_38532477","title":"GSDMD induces hepatocyte pyroptosis to trigger alcoholic hepatitis through modulating mitochondrial dysfunction.","date":"2024","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/38532477","citation_count":8,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55908,"output_tokens":8128,"usd":0.144822,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17698,"output_tokens":4491,"usd":0.100382,"stage2_stop_reason":"end_turn"},"total_usd":0.245204,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"Inflammatory caspases (caspase-1, -4, -5, and -11) cleave GSDMD at the linker between the N-terminal gasdermin-N domain and C-terminal gasdermin-C domain. Cleavage releases the intramolecular autoinhibition imposed by the C-terminal domain on the N-terminal domain, and the freed N-terminal domain is necessary and sufficient to induce pyroptotic cell death. GSDMD-deficient cells resist pyroptosis induced by cytosolic LPS and canonical inflammasome ligands, and IL-1β release is diminished despite intact caspase-1 processing.\",\n      \"method\": \"CRISPR-Cas9 genome-wide screen in mouse bone marrow macrophages; GSDMD knockout cells; domain-mapping experiments with cleavage-resistant and N-terminal-only constructs\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genome-wide genetic screen with rigorous functional follow-up, domain mapping, and loss-of-function confirmed by multiple orthogonal methods; widely replicated\",\n      \"pmids\": [\"26375003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of the human GSDMD C-terminal domain (2.64 Å) reveals that the first loop of GSDMD-C inserts into GSDMD-N to stabilize autoinhibited conformation. The positive-potential surface of GSDMD-N (covered by GSDMD-C in the intact protein) is exposed after caspase cleavage and drives high-order oligomerization via charge-charge interactions. A short segment of GSDMD-N is sufficient to kill bacteria in vitro. SAXS envelope of human GSDMD is consistent with an autoinhibited conformation in solution.\",\n      \"method\": \"X-ray crystallography (GSDMD-C, 2.64 Å); small-angle X-ray scattering (SAXS); site-directed mutagenesis (F283A/F283R); cell-death assays in 293T cells; in vitro bactericidal assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with SAXS and mutagenesis with functional validation in cells and in vitro\",\n      \"pmids\": [\"28928145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Autoprocessing of caspase-4/11 generates a p10 fragment that binds the GSDMD C-terminal domain with high affinity via a hydrophobic interface induced by the autoprocessing-generated β-sheet. Crystal structures of autoprocessed caspase-4/11–GSDMD-C and caspase-1–GSDMD-C complexes reveal a conserved C-domain recognition mode. This C-domain binding promotes dimerization-mediated caspase activation and allows cleavage of GSDMD independently of the canonical cleavage-site tetrapeptide sequence.\",\n      \"method\": \"Crystal structures of caspase-4/11-GSDMD-C and caspase-1-GSDMD-C complexes; biochemical binding assays; autoprocessing mutants; pyroptosis cell assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple crystal structures with mutagenesis and biochemical validation in a single rigorous study\",\n      \"pmids\": [\"32109412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Calcium influx through GSDMD pores in the plasma membrane serves as a signal for cells to recruit the ESCRT-III membrane-repair machinery to damaged membrane areas. Inhibition of ESCRT-III strongly enhances pyroptosis and IL-1β release after canonical or noncanonical inflammasome activation, demonstrating that ESCRT-mediated membrane repair acts downstream of GSDMD pore formation to counteract pyroptotic cell death.\",\n      \"method\": \"Live-cell calcium imaging; pharmacological and genetic inhibition of ESCRT-III; LDH/IL-1β release assays in human and murine macrophages\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (imaging, genetic KD, pharmacological inhibition) replicated in human and murine cells\",\n      \"pmids\": [\"30467171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IRF2, an interferon regulatory factor family transcription factor, binds a unique site in the GSDMD promoter and is required for GSDMD transcription. IRF2-deficient macrophages, endothelial cells, and multiple tissues show substantially reduced GSDMD expression, with corresponding reductions in IL-1β secretion and pyroptosis. Disruption of the single IRF2-binding site abolishes both canonical and noncanonical inflammasome signaling.\",\n      \"method\": \"Forward genetic ENU mutagenesis screen in mice; IRF2 knockout macrophages and tissues; promoter binding assays; IL-1β secretion and pyroptosis assays\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo ENU screen plus mechanistic promoter binding and loss-of-function in multiple cell types\",\n      \"pmids\": [\"31113851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GSDMD undergoes reversible S-palmitoylation at C192 during pyroptosis. The palmitoyl acyltransferase DHHC7 palmitoylates full-length GSDMD to direct its cleavage by caspases. Palmitoylation of the released GSDMD N-terminal fragment (GSDMD-NT) promotes its translocation to the plasma membrane, where the depalmitoylase APT2 then removes the palmitoyl group to unmask C192 and promote GSDMD-NT oligomerization and pore formation. Perturbation of either palmitoylation or depalmitoylation suppresses pyroptosis and increases survival in LPS-induced septic shock.\",\n      \"method\": \"Acyl-RAC palmitoylation assays; site-directed mutagenesis of C192; DHHC7 and APT2 knockout/knockdown; subcellular fractionation; in vivo LPS sepsis model with GSDMD-KO and enzyme-KO mice\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical reconstitution of palmitoylation cycle, mutagenesis, enzyme identification, and in vivo validation with multiple orthogonal methods\",\n      \"pmids\": [\"38538834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In brain endothelial cells (bECs), LPS is internalized via the LBP-CD14 pathway and activates caspase-11 (CASP11), which cleaves GSDMD to cause plasma membrane permeabilization and pyroptosis, leading to BBB disruption. Mice deficient in LBP-CD14 or GSDMD resist LPS-induced BBB breakdown. bEC-targeted delivery of active GSDMD-N opens the BBB independently of LPS. A GSDMD-neutralizing nanobody expressed in bECs prevents K. pneumoniae infection-induced BBB disruption in CASP4-humanized mice.\",\n      \"method\": \"Mouse genetics (GSDMD-KO, LBP/CD14-KO, CASP4-humanized mice); bEC-targeting AAV nanobody delivery; electron microscopy of disrupted BBB; in vitro pyroptosis assays; single-cell RNA-seq\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — comprehensive mouse genetic analyses with multiple KO strains, viral delivery, nanobody rescue, and EM structural validation\",\n      \"pmids\": [\"38632402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Nanobodies (VHHs) raised against human GSDMD that are expressed cytosolically prevent GSDMD-NT oligomerization but not membrane insertion, showing that membrane insertion of GSDMD-NT monomers precedes oligomerization during pore formation. Inhibition of GSDMD pore formation by nanobodies switches cell death from pyroptosis to apoptosis, driven by enhanced caspase-1 activity activating caspase-3. Recombinant antagonistic nanobodies added extracellularly also prevent pyroptosis.\",\n      \"method\": \"Intracellular nanobody expression; extracellular nanobody addition; GSDMD-NT membrane partitioning assays; caspase activity assays; live-cell death readouts\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct mechanistic dissection of oligomerization vs. membrane insertion order using nanobody tools with multiple orthogonal readouts in a single rigorous study\",\n      \"pmids\": [\"39327452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GSDMD-mediated pore formation in endothelial cells in response to cytosolic LPS does not cause cell death but instead restrains endothelial cell proliferation (mitochondrial GSDMD pores DAMPen pyroptosis context discussed in this commentary describing the Huang et al. finding).\",\n      \"method\": \"Commentary/perspective summarizing primary experimental findings from Huang et al. regarding endothelial GSDMD pores and cell proliferation\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — this is a commentary, not a primary experimental paper; the underlying experimental data are not directly reported here\",\n      \"pmids\": [\"32187511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GI-Y1, identified by structure-based virtual screening, binds GSDMD and inhibits its lipid-binding and pore formation by targeting the Arg7 residue of GSDMD-N. GI-Y1 also inhibits mitochondrial binding of GSDMD-N and associated mitochondrial dysfunction, and protects against myocardial I/R injury in vivo.\",\n      \"method\": \"Structure-based virtual screening; direct binding assays; site-directed mutagenesis of Arg7; liposome binding assay; in vivo myocardial I/R mouse model\",\n      \"journal\": \"Basic research in cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding and mutagenesis evidence for Arg7 as functional residue, single lab with in vivo validation\",\n      \"pmids\": [\"37782407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GSDMD is acetylated at Lysine 248, and this acetylation enhances pyroptosis. HDAC4 acts as the specific deacetylase that deacetylates GSDMD at K248, suppressing pyroptosis. Deacetylation of GSDMD impairs its ubiquitination. Phosphorylation of HDAC4 promotes its deacetylase activity toward GSDMD. Protein phosphatase 1 (PP1α and PP1γ) dephosphorylates HDAC4 to inhibit its deacetylase activity on GSDMD, thereby enabling acetylation and pyroptosis.\",\n      \"method\": \"Mass spectrometry identification of acetylation site; site-directed mutagenesis of K248; HDAC4 knockdown/overexpression; PP1 knockdown; ubiquitination assays; in vitro and in vivo pyroptosis assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PTM site identified and functionally validated with mutagenesis; writer/eraser identified; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"38326336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"O-GlcNAcylation of GSDMD at Serine 338 (S338) prevents its interaction with caspase-11 (caspase-4 homolog) and thereby inhibits LPS-induced pyroptosis in endothelial cells. Increased O-GlcNAc stimulation in septic mice reduces endothelial injury and GSDMD cleavage.\",\n      \"method\": \"O-GlcNAcylation site prediction and gene mutation (S338A); Co-IP to assess caspase-4/GSDMD interaction; OGA inhibitor thiamet-G treatment in HUVECs and septic mice; western blot for GSDMD cleavage\",\n      \"journal\": \"Inflammation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PTM site identified by mutagenesis and interaction assay; single lab with in vitro and in vivo evidence\",\n      \"pmids\": [\"37962578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The E3 ligase TRIM21 catalyzes K33-linked polyubiquitination of GSDMD-NT at Lys51, enabling recognition by the cargo receptor SQSTM1/p62 and subsequent selective autophagy-mediated degradation of p30/GSDMD-NT. Scutellarin exploits this pathway to inhibit pyroptosis by degrading p30/GSDMD-NT and by blocking ASC oligomerization.\",\n      \"method\": \"Ubiquitination assays with linkage-specific antibodies; K51R mutagenesis; TRIM21 and p62 knockdown; autophagy flux assays; multiple inflammasome activation models\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PTM (K33-ubiquitin at K51) identified with mutagenesis and E3 ligase identified; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"39824372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"METTL3-mediated m6A modification of GSDMD mRNA is recognized by the m6A reader YTHDF2, which decreases GSDMD mRNA stability and suppresses GSDMD-mediated pyroptosis in breast cancer cells. METTL3 inhibition restores GSDMD expression and enhances pyroptosis.\",\n      \"method\": \"m6A-seq/MeRIP; YTHDF2 RIP assay; mRNA stability assays; METTL3 and YTHDF2 knockdown/overexpression; pyroptosis readouts; in vivo tumor model with METTL3 inhibitor\",\n      \"journal\": \"Apoptosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — m6A writer and reader identified with RNA immunoprecipitation and functional rescue; single lab\",\n      \"pmids\": [\"39627574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SNORD99 promotes 2'-O-methylation of GSDMD mRNA, forming a SNORD99-FBL RNP complex. This modification reduces GSDMD protein levels, thereby suppressing caspase-1/NLRP3-dependent pyroptosis and promoting endometrial cancer progression.\",\n      \"method\": \"RTL-P assay for 2'-O-methylation; RNA-seq after SNORD99 overexpression; co-immunoprecipitation of SNORD99-FBL RNP; ASO-mediated SNORD99 suppression; western blot for GSDMD/caspase-1/NLRP3; electron/optical microscopy of pyroptosis\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel RNA modification of GSDMD identified with RTL-P and RNP pulldown; single lab with multiple methods\",\n      \"pmids\": [\"39450788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GSDMD contributes to mitochondrial dysfunction during pyroptosis: the pore-forming N-terminal of GSDMD localizes to mitochondria (in addition to the plasma membrane) following caspase-dependent cleavage, causing abnormal mitochondrial aggregation and oxidative stress in cochlear marginal cells, which drives inflammation, stria vascularis damage, and cisplatin-induced hearing loss.\",\n      \"method\": \"Gsdmd-KO mice; pharmacological GSDMD inhibition (necrosulfonamide, disulfiram); confocal and electron microscopy for GSDMD-N mitochondrial localization; ROS/membrane potential assays; RNA-seq; cochlear histology\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization of GSDMD-N to mitochondria functionally linked to mitochondrial dysfunction; validated with KO mice and pharmacological inhibition using multiple readouts\",\n      \"pmids\": [\"40067887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A small molecule DMB (6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline) directly activates GSDMD pore formation and pyroptosis without requiring caspase-mediated cleavage of GSDMD, demonstrating that GSDMD can be activated independently of proteolytic processing. Low-level DMB-induced pyroptosis in tumor cells stimulates immune-mediated antitumor responses.\",\n      \"method\": \"High-throughput chemical screen; direct GSDMD pore-formation assays; liposome leakage; tumor models in lymphocyte-deficient mice; cytokine measurements; anti-PD-1 combination studies\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of GSDMD pore formation by small molecule; mechanistic selectivity confirmed; multiple in vivo models\",\n      \"pmids\": [\"39243763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Canonical inflammasomes (NLRP3, NLRC4, NLRP1b, Pyrin, AIM2) all promote GSDMD cleavage in neutrophils, and canonical inflammasome-induced pyroptosis and IL-1β secretion are blunted in GSDMD-knockout neutrophils. In contrast, GSDMD is dispensable for PMA-induced NETosis in neutrophils.\",\n      \"method\": \"GSDMD-KO bone marrow neutrophils; multiple canonical inflammasome activators; NLRP3 gain-of-function (Nlrp3-A350V) transgenic mice; LDH/IL-1β/pyroptosis readouts; PMA-NETosis assay\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — comprehensive genetic loss-of-function across multiple inflammasome platforms; clear positive and negative results for GSDMD role in pyroptosis vs. NETosis\",\n      \"pmids\": [\"35899491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In an experimental sepsis model, NET formation was independent of GSDMD (and PAD4) but required MYD88, indicating that GSDMD is not required for sepsis-induced intravascular NET formation in vivo. Pharmacological GSDMD inhibitors did not reduce PMA-stimulated NET formation ex vivo.\",\n      \"method\": \"Gsdmd/D1/D1l3-/- triple knockout mice; LPS/E. coli sepsis model; pharmacological GSDMD inhibitors; ex vivo PMA-NET assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — negative result (GSDMD dispensable for in vivo NETs in sepsis) established with genetic KO and pharmacological inhibition; single lab\",\n      \"pmids\": [\"39777764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Caspase-8 and GSDMD are both required for the development of MLKL-independent ileitis in mice with epithelial FADD deficiency, placing GSDMD downstream of caspase-8 in a pyroptosis-like death pathway in intestinal epithelial cells that is distinct from necroptosis.\",\n      \"method\": \"Genetic epistasis: IEC-specific FADD-KO, caspase-8-KO, MLKL-KO, GSDMD-KO mice and combinations; histological assessment of colitis/ileitis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean epistasis with multiple double and triple KO combinations defining pathway position in vivo\",\n      \"pmids\": [\"32362323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GSDMD deficiency in cardiomyocytes (cardiomyocyte-specific CKO) reduces TAC-induced pyroptosis, myocardial hypertrophy, and fibrosis. GSDMD-mediated pyroptosis in this context activates JNK and p38 signaling pathways (but not ERK or Akt), linking GSDMD-driven pyroptosis to downstream kinase-mediated cardiac remodeling.\",\n      \"method\": \"Cardiomyocyte-specific GSDMD-CKO mice; TAC-induced pressure overload; echocardiography; western blot for JNK/p38/ERK/Akt phosphorylation; histology\",\n      \"journal\": \"Clinical and experimental hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO with pathway analysis; single lab\",\n      \"pmids\": [\"36906959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GSDMD in macrophages contributes to mitochondrial perforation and mitochondrial DNA leakage, subsequently activating the STING-IRF3/NF-κB axis. GSDMD also regulates macrophage migration via cytokine secretion in the context of atherosclerosis.\",\n      \"method\": \"Gsdmd-/-ApoE-/- mice; bone marrow transplantation; AAV-F4/80-shGSDMD macrophage-specific knockdown; single-cell RNA-seq; STING pathway analysis; mtDNA leakage assays\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — macrophage-specific KD combined with mtDNA/STING pathway mechanistic analysis; single lab\",\n      \"pmids\": [\"38695170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GSDMD-NT from pyroptotic macrophage-derived microvesicles (containing GSDMD-N-expressing mitochondria) is transferred to neutrophils via microvesicles, inducing mitochondrial dysfunction and triggering NETs formation through the mitochondrial ROS/GSDMD axis in the context of sepsis.\",\n      \"method\": \"Macrophage-neutrophil co-culture with microvesicles; flow cytometry; confocal microscopy for mitochondrial transfer; mtROS measurement; disulfiram (GSDMD inhibitor) in vivo sepsis model\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic intercellular transfer established with imaging and functional assays; single lab\",\n      \"pmids\": [\"38169726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GSDMD knockout in GSDMD-/- mice or GSDMD knockdown (dimethyl fumarate) inhibits GSDMD activation and reduces NETs formation and mitochondrial DNA leakage into the neutrophil cytosol. GSDMD causes mtDNA to leak into the cytosol during lung ischemia/reperfusion, activating the cGAS-STING pathway and stimulating NETs formation.\",\n      \"method\": \"GSDMD-KO mice; disulfiram pharmacological inhibition; mtDNA cytoplasmic fractionation; cGAS-STING pathway inhibition; in vivo lung I/R model\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological GSDMD inhibition with mechanistic pathway (mtDNA-cGAS-STING) in vivo; single lab\",\n      \"pmids\": [\"37794018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CHMP4B and VPS4A (ESCRT-III components) interact with GSDMD (confirmed by Co-IP) and localize as puncta at injured plasma membranes containing GSDMD-NT. Depletion of CHMP4B or VPS4A enhances GSDMD-mediated pore formation and pyroptotic indicators, while overexpression reduces them, demonstrating that the ESCRT machinery directly counteracts GSDMD pores through membrane remodeling in endometrial carcinoma cells.\",\n      \"method\": \"Co-immunoprecipitation of GSDMD with CHMP4B and VPS4A; siRNA knockdown and overexpression; electron microscopy of membrane perforations; fluorescence confocal microscopy of CHMP4B/VPS4A puncta at GSDMD-NT membrane sites; PI/LDH/IL-1β/Ca2+ assays\",\n      \"journal\": \"Biochimica et biophysica acta. General subjects\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct interaction confirmed by Co-IP with functional membrane repair readouts; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"37931722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GSDMD deficiency in the acute phase of myocardial I/R protects the heart, but in the chronic phase GSDMD deficiency aggravates injury. Mechanistically, GSDMD deficiency induces activation of poly(ADP-ribosyl)ation (PARylation) and consumption of NAD+ and ATP, leading to cardiomyocyte apoptosis. PARP-1 inhibitor PJ34 reduces injury caused by GSDMD deficiency.\",\n      \"method\": \"GSDMD-KO mice; acute and chronic I/R timepoints; PARylation assays; NAD+/ATP measurements; PJ34 pharmacological rescue; western blot and histology\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with biochemical mechanism (PARylation/NAD+) and pharmacological rescue; single lab\",\n      \"pmids\": [\"35783187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"JX06 covalently modifies Cys39/Cys192 residues of GSDMD, inhibiting accumulation of GSDMD-NT and pore formation in the plasma membrane, thereby suppressing PANoptosis and multiple organ injury in heat stress and sepsis models.\",\n      \"method\": \"Covalent modification mass spectrometry; GSDMD-KO rescue experiments; in vitro pore-formation assays; in vivo heat stress and sepsis MODS models; cell death assays\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — covalent binding to specific cysteines identified by MS with in vitro pore-formation and in vivo validation; single lab\",\n      \"pmids\": [\"39848475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GSDMD knockout reduces skeletal muscle atrophy in septic mice by blocking the IL-18/AMPK signaling pathway, and specifically reduces markers of the ubiquitin-proteasome system and autophagy pathways. GSDMD-NT levels are elevated in skeletal muscle of septic mice, linking pyroptosis execution by GSDMD to downstream IL-18 secretion that drives muscle wasting via AMPK.\",\n      \"method\": \"Gsdmd-KO mice; CLP sepsis model; siRNA knockdown in C2C12 cells; AMPK phosphorylation assays; muscle atrophy marker expression (Atrogin-1, MuRF1); IL-18 measurements\",\n      \"journal\": \"Shock\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO with defined signaling pathway (IL-18/AMPK) in vivo and in vitro; single lab\",\n      \"pmids\": [\"39227368\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GSDMD is a cytosolic executioner protein that is maintained in an autoinhibited conformation by intramolecular interactions between its C-terminal (gasdermin-C) and N-terminal (gasdermin-N) domains; inflammatory caspases (caspase-1, -4, -5, -11) recognize and cleave the interdomain linker—with autoprocessed caspase-4/11 p10 engaging a hydrophobic interface on the GSDMD-C domain to drive cleavage independently of tetrapeptide sequence—releasing GSDMD-NT, which undergoes DHHC7-mediated palmitoylation at C192 to traffic to the plasma membrane, where APT2-mediated depalmitoylation unmasks C192 and enables oligomerization into large membrane pores that drive pyroptotic cell death, IL-1β/IL-18 release, and calcium influx; the ESCRT-III membrane-repair machinery is recruited downstream of calcium influx to reseal pores and antagonize pyroptosis; GSDMD-NT also localizes to mitochondria causing dysfunction; GSDMD expression is transcriptionally driven by IRF2 binding a unique promoter element; and GSDMD activity is further regulated by post-translational modifications including acetylation (at K248, reversed by HDAC4), K33-linked ubiquitination (at K51 by TRIM21, targeting it for autophagic degradation), and O-GlcNAcylation (at S338, blocking caspase-4 interaction).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GSDMD is the terminal pore-forming executioner of pyroptosis, an inflammatory programmed cell death triggered by inflammatory caspase activation [#0]. In its resting state GSDMD is autoinhibited: the first loop of the C-terminal gasdermin-C domain inserts into the N-terminal gasdermin-N domain, masking a positively charged oligomerization surface; inflammatory caspases-1, -4, -5, and -11 cleave the interdomain linker to liberate GSDMD-NT, which is both necessary and sufficient to kill the cell [#0, #1]. Caspase recognition occurs through a conserved hydrophobic interface on GSDMD-C engaged by the autoprocessed caspase p10 fragment, allowing cleavage independently of the canonical tetrapeptide site [#2]. Freed GSDMD-NT inserts into the plasma membrane as monomers and then oligomerizes into large pores, a temporal order resolved by intracellular nanobodies that block oligomerization without preventing membrane insertion [#7]; this trafficking is gated by a palmitoylation cycle in which DHHC7 palmitoylates C192 and APT2 subsequently depalmitoylates it to license oligomerization [#5]. The resulting pores drive pyroptotic lysis, IL-1\\u03b2/IL-18 release, and calcium influx, the last of which recruits the ESCRT-III machinery (CHMP4B, VPS4A) to repair damaged membrane and antagonize pyroptosis [#3, #24]. GSDMD operates across canonical (NLRP3, NLRC4, NLRP1b, Pyrin, AIM2) and noncanonical inflammasome platforms and also lies downstream of caspase-8 in a FADD-restrained epithelial death pathway [#17, #19]. GSDMD-NT additionally localizes to mitochondria, causing aggregation, oxidative stress, and mtDNA leakage that activates STING/cGAS signaling [#15, #21]. Expression is controlled transcriptionally by IRF2 binding a unique promoter element [#4], and GSDMD activity is further tuned by acetylation at K248 (reversed by HDAC4), K33-linked ubiquitination at K51 by TRIM21 directing p62-mediated autophagic degradation, and O-GlcNAcylation at S338 that blocks caspase engagement [#10, #12, #11]. GSDMD can also be activated pharmacologically without cleavage, and its pore can be blocked by small molecules and covalent cysteine modifiers, establishing it as a therapeutic target in sepsis, ischemia/reperfusion, and tumor immunity [#16, #9, #26].\",\n  \"teleology\": [\n    {\n      \"year\": 2015,\n      \"claim\": \"Established GSDMD as the essential effector of pyroptosis, answering what links inflammatory caspase activation to inflammatory cell death and cytokine release.\",\n      \"evidence\": \"Genome-wide CRISPR screen in mouse macrophages with GSDMD knockout and domain-mapping constructs\",\n      \"pmids\": [\"26375003\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of autoinhibition not yet defined\", \"Mechanism of membrane pore assembly unknown\", \"Caspase recognition mode not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Resolved the structural logic of autoinhibition and oligomerization, explaining how cleavage converts a dormant protein into a membrane-disrupting effector.\",\n      \"evidence\": \"Crystal structure of GSDMD-C, SAXS of full-length GSDMD, and mutagenesis with cell-death and bactericidal assays\",\n      \"pmids\": [\"28928145\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pore architecture in the membrane not visualized\", \"Order of membrane insertion vs oligomerization unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified a cell-intrinsic brake on pyroptosis, showing pore-induced calcium influx triggers ESCRT-III membrane repair to limit cell death.\",\n      \"evidence\": \"Live-cell calcium imaging with genetic and pharmacological ESCRT-III inhibition in human and murine macrophages\",\n      \"pmids\": [\"30467171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical link between GSDMD pores and ESCRT recruitment not defined here\", \"Stoichiometry of repair vs pore formation unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined transcriptional control of GSDMD, showing IRF2 sets the cellular threshold for inflammasome competence.\",\n      \"evidence\": \"ENU mutagenesis screen, IRF2 knockout cells/tissues, and promoter binding assays\",\n      \"pmids\": [\"31113851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals upstream of IRF2 not defined\", \"Other transcriptional regulators not excluded\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Explained how caspases recognize GSDMD independently of a tetrapeptide motif, identifying a conserved C-domain hydrophobic interface engaged by autoprocessed caspase p10.\",\n      \"evidence\": \"Crystal structures of caspase-4/11- and caspase-1-GSDMD-C complexes with biochemical and cellular validation\",\n      \"pmids\": [\"32109412\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether all caspases use identical interface kinetics unclear\", \"Regulation of caspase-GSDMD docking in cells not addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Positioned GSDMD downstream of caspase-8 in a FADD-restrained epithelial death pathway distinct from necroptosis, broadening its pathway context beyond inflammatory caspases.\",\n      \"evidence\": \"Genetic epistasis with IEC-specific FADD, caspase-8, MLKL, and GSDMD knockout combinations in mice\",\n      \"pmids\": [\"32362323\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct caspase-8 cleavage of GSDMD not biochemically shown here\", \"Tissue specificity of this pathway unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Delineated GSDMD's role across inflammasome platforms in neutrophils and dissociated it from NETosis, clarifying which neutrophil functions depend on GSDMD.\",\n      \"evidence\": \"GSDMD-knockout neutrophils with multiple canonical inflammasome activators and PMA-NETosis assays\",\n      \"pmids\": [\"35899491\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conditions under which GSDMD contributes to NETs remained unresolved\", \"Neutrophil-specific pore dynamics not measured\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified a palmitoylation/depalmitoylation cycle (DHHC7, APT2) at C192 that gates GSDMD trafficking and pore assembly, adding a lipid-modification checkpoint to activation.\",\n      \"evidence\": \"Acyl-RAC assays, C192 mutagenesis, DHHC7/APT2 perturbation, and in vivo LPS sepsis models\",\n      \"pmids\": [\"38538834\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Spatial coordination of palmitoylation cycle with caspase cleavage unclear\", \"Whether the cycle applies to all activation routes unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Resolved the kinetic order of pore formation, showing GSDMD-NT inserts as monomers before oligomerizing, and that blocking oligomerization reroutes death to apoptosis.\",\n      \"evidence\": \"Intracellular and extracellular nanobodies with membrane partitioning and caspase activity readouts\",\n      \"pmids\": [\"39327452\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the inserted monomer intermediate not determined\", \"In vivo relevance of pyroptosis-to-apoptosis switch not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated GSDMD pores can be activated pharmacologically without cleavage and exploited for antitumor immunity, decoupling pore formation from proteolytic processing.\",\n      \"evidence\": \"High-throughput chemical screen identifying DMB with liposome leakage and tumor models\",\n      \"pmids\": [\"39243763\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which DMB bypasses autoinhibition not fully defined\", \"Selectivity over other gasdermins not detailed here\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established GSDMD-NT mitochondrial localization as a direct driver of organelle dysfunction and oxidative stress, expanding pore action beyond the plasma membrane.\",\n      \"evidence\": \"Gsdmd-KO mice, pharmacological inhibition, and microscopy/ROS assays in cochlear cells\",\n      \"pmids\": [\"40067887\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Targeting signal directing GSDMD-NT to mitochondria unknown\", \"Relative contribution of mitochondrial vs plasma membrane pores unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Mapped post-transcriptional and post-translational control nodes (acetylation/HDAC4, K33-ubiquitination/TRIM21-p62, O-GlcNAcylation, m6A, 2'-O-methylation) that tune GSDMD abundance and activation.\",\n      \"evidence\": \"Mass spectrometry, site-directed mutagenesis, writer/eraser/reader identification, and RNA-modification assays across multiple disease models\",\n      \"pmids\": [\"38326336\", \"39824372\", \"37962578\", \"39627574\", \"39450788\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cross-talk and hierarchy among modifications not established\", \"Most are single-lab findings without independent replication\", \"Physiological contexts in which each modification dominates unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected GSDMD to context-dependent disease outcomes via mtDNA-STING signaling, cytokine-driven tissue damage, and intercellular transfer of GSDMD-N-bearing mitochondria.\",\n      \"evidence\": \"Tissue-specific KO/knockdown mice in atherosclerosis, sepsis, and ischemia/reperfusion with pathway and microvesicle transfer assays\",\n      \"pmids\": [\"38695170\", \"37794018\", \"38169726\", \"39227368\", \"35783187\", \"36906959\", \"38632402\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical mechanism of intercellular GSDMD transfer not fully resolved\", \"Acute vs chronic dual roles of GSDMD remain context-dependent\", \"Many findings are single-lab disease-model studies\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unified structural model of the assembled GSDMD membrane pore, the determinants of mitochondrial versus plasma-membrane targeting, and the integration of competing PTM checkpoints into a single regulatory logic remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of the assembled pore in the timeline\", \"Mechanism selecting mitochondrial vs plasma membrane localization unknown\", \"Hierarchy among transcriptional, RNA, and protein modifications unestablished\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [1, 9]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 1, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5, 7, 24]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [15, 21]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 4, 17]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [3, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CASP1\", \"CASP4\", \"CASP11\", \"DHHC7\", \"APT2\", \"TRIM21\", \"CHMP4B\", \"VPS4A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}